Roche touts PD-L1 med's latest lung cancer results; Judge rules for Endo in Opana ER patent suit;

> Roche's ($RHHBY) cancer immunotherapy shrank lung cancer tumors in a Phase II study, putting the company one step closer to winning FDA approval for its "breakthrough" designated med. Release

> Endo International ($ENDP) said a U.S. federal court upheld two Opana ER patents, a ruling that is expected to prompt Allergan ($AGN) to pull the generic version its Actavis unit sells. Release

> Biogen ($BIIB) said an extension study reinforced the long-term benefits of its hemophilia B drug Alprolix. Release

> HIV drug specialist ViiV Healthcare handed off its corporate communications work to Porter Novelli, PRWeek reports. Story

> A Hill Dermaceuticals sales rep lost her wrongful termination suit against the company, which said it fired her because she started her own business on the side and disparaged Hill's products. Report

And Finally... Video game developers are amping up work on health-related products, but worry about FDA scrutiny. Report

Suggested Articles

The FDA's ad watchdog served its most serious violation to Alkermes Wednesday—and it took the unusual step of announcing that violation to the world.

Merck and Roche are no strangers to sparring with their I-O meds Keytruda and Tecentriq, but in TNBC, Keytruda's latest data take the prize.

Pfizer is doubling down on real-world data in HR-positive, HER2-negative breast cancer patients to boost its case for blockbuster Ibrance.